Rigel Pharmaceuticals RIGL Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 93.4%+0.1pp | 93.3%+0.2pp | 93.1%+1.6pp | 91.5%+1.9pp | 89.6%0.0pp | |
| Operating margin | 41.6%-1.1pp | 42.6%+0.5pp | 42.2%+3.1pp | 39%+17.4pp | 21.6%+8.1pp | |
| Net margin | 121.5%-3.2pp | 124.7%+84.6pp | 40.2%+3.7pp | 36.5%+18.2pp | 18.3%+8.6pp | |
| Efficiency | ||||||
| Asset turnover | 0.9×0.0× | 0.9×-0.6× | 1.5×-0.1× | 1.6×+0.3× | 1.3×+0.1× | |
| Liquidity | ||||||
| Current ratio | 2.6×+0.2× | 2.4×+0.1× | 2.3×+0.3× | 2×-0.2× | 2.2×+0.1× | |
| Leverage | ||||||
| Debt-to-equity | 0.2×0.0× | 0.2×+0.2× | 0×— | —— | —— | |
| Net debt / EBITDA | 0.3×0.0× | 0.3×+0.7× | -0.4×+0.1× | -0.5×— | —— | |
| Per Share | ||||||
| Book value per share | $20.31-2.2% | $20.78+238% | $6.14+36.1% | $4.51+341% | $1.02+450% | |
| Valuation | ||||||
| Market capitalization | $684.39M+102% | $777.42M+53.0% | $508.16M+52.0% | $334.21M+4.0% | $321.35M+8.5% | |
| Price / earnings | 1.9×-7.2× | 2.1×-2.4× | 4.5×+1.1× | 3.4×— | —— | |
| Price / sales | 2.3×+0.6× | 2.6×+0.8× | 1.8×+0.6× | 1.2×-0.3× | 1.6×-0.1× | |
| Price / book | 1.7×-16.5× | 2×-2.3× | 4.3×— | —— | —— | |
| EV / EBITDA | 5.7×-0.6× | 6.4×+2.6× | 3.8×+1.2× | 2.6×— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Rigel Pharmaceuticals's profit margins?
- Rigel Pharmaceuticals (RIGL) runs a 93.4% gross margin and a 41.6% operating margin, with a 121.5% net margin.
- Where do Rigel Pharmaceuticals's ratios come from?
- Every ratio is computed from Rigel Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
